Expression of Ki-67 in premalignant and malignant lesion of cervix in tertiary care hospital in Uttar Pradesh

Pratima Singh; Kanchan Garg; Ankita Singh; Shambhavi Tripathi

doi:10.18203/2320-6012.ijrms20231318

Authors

Pratima Singh Department of Pathology, Hind Institute of Medical Sciences, Mau, Sitapur, Uttar Pradesh, India
Kanchan Garg Department of Pathology, Hind Institute of Medical Sciences, Mau, Sitapur, Uttar Pradesh, India
Ankita Singh Department of Pathology, Hind Institute of Medical Sciences, Mau, Sitapur, Uttar Pradesh, India
Shambhavi Tripathi Department of Pathology, Hind Institute of Medical Sciences, Mau, Sitapur, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20231318

Keywords:

Cervical cancer, Ki-67, Squamous cell carcinoma

Abstract

Background: cancer is fast emerging as one of the most common causes of death related morbidities throughout the world. As far as India is concerned. Ki-67 is an ideal marker to assess the cellular proliferation. The study aimed to evaluate the proliferative activity by using Ki-67 in premalignant and malignant lesion of cervix. To study the various histomorphology features of cervical lesion and grading it into cervical intraepithelial neoplasia and malignant lesion. To access the expression of Ki 67 in different grade of lesions.

Methods: The study was carried in 60 cases of cervical biopsy that included 30 cases of CIN 1, CIN2 and 30 cases of CIN 3, SCC. Ki-67 staining was done on all cases which were diagnosed histologically as CIN or cervical carcinoma. The result was categorized in grading 1,2,3.

Results: Ki-67 expression was studied in all cases. There was an increase in the intensity of Ki-67 from CIN to carcinoma. The focal positivity in low grade lesion to diffuse positivity in higher grade lesion was seen in our study.

Conclusions: In this study, Ki-67 expression was helpful in differentiating dysplastic lesion from carcinoma and helps in confirming the histopathological diagnosis. Therefore Ki-67 marker could be used as biomarker in the evaluation of the proliferative activity and progressive potential of dysplastic and neoplastic changes.

Metrics

Metrics Loading ...

References

Ferlay J, Shin HR, Bray F, Forman D,Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.

Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C, Geater A. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res. 2005;31(3):268-76.

Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-22.

Ancuţa E, Ancuţa C, Cozma LG, Iordache C, Anghelache-Lupaşcu I, Anton E, et al. Tumor biomarkers in cervical cancer: focus on Ki-67 proliferation factor and E-cadherin expression. Rom J Morphol Embryol. 2009;50(3):413-8.

Gogoi PK, Borgohain M, Sonowal R. Ki-67 expression and apoptotic index in premalignant and malignant lesions of uterine cervix. International Journal of Contemporary Medical Research. 2016;3(11):3401-5.

Kanthiya K, Khunnarong J, Tangjitgamol S, Puripat N, Tanvanich S. Expression of the p16 and Ki67 in Cervical Squamous Intraepithelial Lesions and Cancer. Asian Pac J Cancer Prev. 2016;17(7):3201-6.

Hebbar A, Murthy VS. Role of p16/INK4a and Ki-67 as specific biomarkers for cervical intraepithelial neoplasia: An institutional study. J Lab Physicians. 2017;9(2):104-10.

Ayatollahi H, Jahangard S, Naji S, Yekta Z. Investigation of the P16 and Ki67 Predictive Effect on the Progression of Cervical Intraepithelial Neoplasia Grade 1 in Shahid Motahari Hospital of Urmia, Iran. J Obstet Gynecol Cancer Res. 2022;7(3):206-12.

Shi Q, Xu L, Yang R, Meng Y, Qiu L. Ki-67 and P16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions. Oncol Lett. 2019;18(2):1351-5.

Mishra R, Vahikar SU, Kumari Mitra S, Nagger S, Shrivastava K. The use of molecular markers (Ki67 & p53) in premalignant and malignant cervical neoplasms. Tropical Journal of Pathology and Microbiology. 2016;2(1):3-8.

Ghosh A, M N, Padmanabha N, Kini H. Assessment of p16 and Ki67 Immunohistochemistry Expression in Squamous Intraepithelial Lesion with Cytohistomorphological Correlation. Iran J Pathol. 2020;15(4):268-73.

Sarma U, Das GC, Sarmah B. Predictive Value of Marker of Proliferation Ki-67 and Cell Cycle Dependent Protein kinase Inhibitor P16INK4a in Cervical Biopsy to Determine Its Biological Behaviour. Asian Pac J Cancer Prev. 2021;22(7):2237-41.

O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds.Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005:607-29.

National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2014.

Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-22.

Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018;127(2):175-86.

Yu L, Fei L, Liu X, Pi X, Wang L, Chen S. Application of p16/Ki-67 dual-staining cytology in cervical cancers. J Cancer. 2019 ;10(12):2654-60.

Jiang MY, Wu Z, Li T, Yu L, Zhang SK, Zhang X, et al. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women. Cancer Prev Res (Phila). 2020;13(2):163-72.

Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, et al. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncol. 2019;5(2):181-6.

Gaber G, El Achy S, Khedr GA, Parimi V, Helenowksi I, Donnelly ED, et al. Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy. Am J Clin Oncol. 2021;44(2):58-67.

Shiohara S, Shiozawa T, Miyamoto T, et al. Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch. 2005;446(6):626-33.

Ancuţa E, Ancuţa C, Cozma LG, Iordache C, Anghelache-Lupaşcu I, Anton E, Carasevici E, Chirieac R. Tumor biomarkers in cervical cancer: focus on Ki-67 proliferation factor and E-cadherin expression. Rom J Morphol Embryol. 2009;50(3):413-8.

Anuranjeeta, Sharma S, Shukla KK, Anshu A. Evaluation of morphological changes in histopathological images of ovarian and breast cancer tissues and its correlation with biochemical parameters. Res. J. Biotech. 2017;12(4):30-8.

Al-Jashamy K, Al-Naggar RA, San P, Mashani M. Histopathological findings for cervical lesions in Malaysian women. Asian Pac J Cancer Prev. 2009;10(6):1159-62.

Painter JT, Clayton NP, Herbert RA. Useful immunohistochemical markers of tumor differentiation. Toxicol Pathol. 2010;38(1):131-41.

Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, Medeiros LJ, Vega F, Younes A, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica. 2012;97(7):1080-4.

Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 2007;131(10):1561-7.

He J, Zhang C, Shi Q, Bao F, Pan X, Kuai Y, et al. Association between Immunohistochemistry Markers and Tumor Features and Their Diagnostic and Prognostic Values in Intrahepatic Cholangiocarcinoma. Comput Math Methods Med. 2022;2022:8367395.

Jensen KE, Hannibal CG, Nielsen A, Jensen A, Nohr B, Munk C, et al. Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994–2003. Eur J Cancer. 2008;44:(14)2003-17.

Ibfelt E, Kjaer SK, Johansen C, Hogdall C, Steding-Jessen M, Frederiksen K, et al. Socioeconomic position and stage of cervical cancer in Danish women diagnosed 2005 to 2009. Cancer Epidemiol Biomarkers Prev. 2012;21:(5)835-42.

Lassise DL, Savitz DA, Hamman RF, Barón AE, Brinton LA, Levines RS. Invasive cervical cancer and intrauterine device use. Int J Epidemiol. 1991;20(4):865-70.

Spotnitz ME, Natarajan K, Ryan PB, Westhoff CL. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users. Obstet Gynecol. 2020;135(2):319-327.

Dasgupta A, Sinha RN, Paul B, Bandyopadhyay L, Banerjee R, Suman S. A study on unhealthy cervix and its risk factors among currently married women of reproductive age group attending an urban health centre of Kolkata. Int J Community Med Public Health 2019;6:2133-8.

Cooper DB, McCathran CE. Cervical Dysplasia. [Updated 2022 Jul 12]. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2022 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430859/ Accessed 9 June 2014.

Mello V, Sundstrom RK. Cervical Intraepithelial Neoplasia. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK544371/. Accessed 9 June 2014.